Form 4: Castle Biosciences Director Increases Common Stock Holdings and Receives New RSU Grant

Ellen Goldberg, a Director at Castle Biosciences Inc., has increased her direct beneficial ownership of common stock through RSU vesting and received a new grant of Restricted Stock Units.

Summary

• On May 21, 2025, Ellen Goldberg, a Director of Castle Biosciences Inc. (CSTL), acquired 8,673 shares of common stock upon the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Ms. Goldberg's direct beneficial ownership of common stock increased to 27,254 shares.
• Additionally, on May 22, 2025, Ms. Goldberg was granted 13,667 new Restricted Stock Units.
• Each RSU represents the right to receive one share of the Issuer's Common Stock.
• The 8,673 RSUs that vested on May 21, 2025, were set to vest in full on the earlier of the one-year anniversary of May 23, 2025, or the day immediately preceding the next Annual Meeting of Stockholders following the grant date.
• The newly granted 13,667 RSUs will vest in full on the earlier of the one-year anniversary of May 22, 2026, or the day immediately preceding the next Annual Meeting of Stockholders following the grant date.

Sentiment

Score: 7

Explanation: The document reflects positive sentiment as it details routine insider equity compensation, including an increase in direct common stock ownership and a new RSU grant, which aligns director interests with shareholders.

Positives

• The acquisition of 8,673 common shares through RSU vesting increases the direct beneficial ownership of a company director, aligning their interests further with shareholders.
• The grant of an additional 13,667 Restricted Stock Units to a director indicates continued compensation and incentivization for long-term performance and commitment to the company.

Future Outlook

The newly granted Restricted Stock Units (13,667 units) are scheduled to vest in full on the earlier of May 22, 2026, or the day immediately preceding the next Annual Meeting of Stockholders following the grant date.

Industry Context

This Form 4 filing details routine insider equity compensation, which is a standard practice across industries to align management and director interests with shareholder value. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director can be seen as a positive signal of confidence in the company's future and better alignment of interests.

Next Steps

• Future vesting of the 13,667 Restricted Stock Units on the earlier of May 22, 2026, or the day immediately preceding the next Annual Meeting of Stockholders.

Key Dates

Keywords

Castle Biosciences, CSTL, Ellen Goldberg, Director, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Beneficial Ownership, Equity Compensation